| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.
|
Cancer Cell
|
2006
|
21.66
|
|
2
|
A randomized trial of bevacizumab for newly diagnosed glioblastoma.
|
N Engl J Med
|
2014
|
9.19
|
|
3
|
The transcriptional network for mesenchymal transformation of brain tumours.
|
Nature
|
2009
|
8.44
|
|
4
|
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
|
N Engl J Med
|
2015
|
5.71
|
|
5
|
FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis.
|
Cancer Cell
|
2011
|
3.58
|
|
6
|
Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma.
|
Cancer Res
|
2005
|
3.10
|
|
7
|
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.
|
J Clin Oncol
|
2007
|
3.07
|
|
8
|
Retracted
Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig2-positive glioma tumor-initiating cells.
|
Cancer Res
|
2013
|
2.75
|
|
9
|
The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.
|
Genes Dev
|
2011
|
2.48
|
|
10
|
Retracted
Glioma-associated cancer-initiating cells induce immunosuppression.
|
Clin Cancer Res
|
2010
|
2.24
|
|
11
|
Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death.
|
J Natl Cancer Inst
|
2007
|
2.23
|
|
12
|
Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway.
|
Mol Cancer Ther
|
2010
|
2.00
|
|
13
|
Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma.
|
Clin Cancer Res
|
2006
|
1.91
|
|
14
|
YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma.
|
Clin Cancer Res
|
2005
|
1.81
|
|
15
|
MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma.
|
Neuro Oncol
|
2009
|
1.69
|
|
16
|
The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
|
Cancer
|
2005
|
1.34
|
|
17
|
IDH1 and IDH2 mutations in gliomas.
|
Curr Neurol Neurosci Rep
|
2013
|
1.32
|
|
18
|
Glioma biology and molecular markers.
|
Cancer Treat Res
|
2015
|
1.24
|
|
19
|
A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies.
|
Neuro Oncol
|
2008
|
1.23
|
|
20
|
Exploratory analysis of the copy number alterations in glioblastoma multiforme.
|
PLoS One
|
2008
|
1.17
|
|
21
|
Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells.
|
J Proteome Res
|
2010
|
1.09
|
|
22
|
Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma.
|
J Neurooncol
|
2009
|
1.07
|
|
23
|
A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
|
Stem Cells
|
2014
|
1.07
|
|
24
|
Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype.
|
Oncotarget
|
2010
|
1.05
|
|
25
|
Effective elimination of cancer stem cells by a novel drug combination strategy.
|
Stem Cells
|
2013
|
1.04
|
|
26
|
Phase 2 trial design in neuro-oncology revisited: a report from the RANO group.
|
Lancet Oncol
|
2012
|
1.01
|
|
27
|
REST regulates oncogenic properties of glioblastoma stem cells.
|
Stem Cells
|
2012
|
1.00
|
|
28
|
Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway.
|
J Neurooncol
|
2012
|
0.95
|
|
29
|
Isolation and perivascular localization of mesenchymal stem cells from mouse brain.
|
Neurosurgery
|
2010
|
0.93
|
|
30
|
A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma.
|
Neuro Oncol
|
2010
|
0.93
|
|
31
|
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme.
|
Neuro Oncol
|
2008
|
0.93
|
|
32
|
ELTD1, a potential new biomarker for gliomas.
|
Neurosurgery
|
2013
|
0.91
|
|
33
|
Glycomic and transcriptomic response of GSC11 glioblastoma stem cells to STAT3 phosphorylation inhibition and serum-induced differentiation.
|
J Proteome Res
|
2010
|
0.90
|
|
34
|
A practical review of prognostic correlations of molecular biomarkers in glioblastoma.
|
Neurosurg Focus
|
2015
|
0.90
|
|
35
|
Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.
|
Neoplasia
|
2013
|
0.88
|
|
36
|
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma.
|
J Neurooncol
|
2010
|
0.87
|
|
37
|
Experimental validation of 5 in-silico predicted glioma biomarkers.
|
Neuro Oncol
|
2013
|
0.86
|
|
38
|
Brain tumor stem cells.
|
Curr Probl Cancer
|
2008
|
0.85
|
|
39
|
Incorporation of biomarker assessment in novel clinical trial designs: personalizing brain tumor treatments.
|
Curr Oncol Rep
|
2011
|
0.83
|
|
40
|
Polar lipid remodeling and increased sulfatide expression are associated with the glioma therapeutic candidates, wild type p53 elevation and the topoisomerase-1 inhibitor, irinotecan.
|
Glycoconj J
|
2009
|
0.82
|
|
41
|
Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme.
|
J Neurooncol
|
2012
|
0.79
|
|
42
|
Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
|
Neurosurg Focus
|
2015
|
0.79
|
|
43
|
Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
|
Cancer
|
2013
|
0.79
|
|
44
|
Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma.
|
Cancer
|
2011
|
0.78
|
|
45
|
Retraction: Novel HSP90 inhibitor NVP-HSP990 targets cell-cycle regulators to ablate Olig 2-positive glioma tumor-initiating cells.
|
Cancer Res
|
2014
|
0.75
|
|
46
|
Bevacizumab is Effective for Recurrent Papillary Tumor of the Pineal Region: First Report.
|
Case Rep Oncol
|
2013
|
0.75
|
|
47
|
Medulloblastoma: molecular classifications and prognostic associations.
|
Oncology (Williston Park)
|
2012
|
0.75
|